nach oben

Erschienen in:

06.01.2021

Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms

verfasst von: Chiara Liverani, Alberto Bongiovanni, Laura Mercatali, Federica Pieri, Chiara Spadazzi, Giacomo Miserocchi, Giandomenico Di Menna, Flavia Foca, Sara Ravaioli, Alessandro De Vita, Claudia Cocchi, Giulio Rossi, Federica Recine, Toni Ibrahim

Erschienen in: Endocrine Pathology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a rare and heterogeneous subgroup of tumors with a challenging management because of their extremely variable biological and clinical behaviors. Due to their different prognosis, there is an urgent need to identify molecular markers which would enable to discriminate between grade 3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), despite both being diagnosed mainly on the basis of proliferation index and cell differentiation. DLL3, a negative Notch regulator, is a promising molecular target highly expressed in several tumors with neuroendocrine features. We conducted a retrospective analysis of DLL3, RB1, and PD-L1 expression by immunohistochemistry (IHC), in formalin-fixed, paraffin-embedded (FFPE) samples from 47 patients with GEP-NENs. Then, we correlated the results with patients’ clinical features and outcome. The absence of DLL3 expression in 5 well-differentiated GEP-NETs with high-grade features (G3 NET), and the presence of DLL3 in 76.9% of poorly-differentiated NECs (G3 NEC), highlights DLL3 expression as a marker of G3 NECs (p = 0.007). DLL3 expression was correlated with RB1-loss (p < 0.001), negative ⁶⁸ Ga-PET/CT scan (p = 0.001), and an unfavorable clinical outcome, with important implications for treatment response and patient’s follow-up. Median progression-free survival (PFS) and overall survival (OS) were 22.7 months (95% CI 6.1–68.8) and 68.8 months (95% CI 26.0–78.1), respectively, in patients with DLL3-negative tumor compared with 5.2 months (95% CI 2.5–18.5) and 9.5 months (95% CI 2.5–25.2), respectively, in patients with DLL3-positive tumor (PFS p = 0.0083, OS p = 0.0071). Therefore, combined with morphological cell analysis, DLL3 could represent a valuable histological marker, for the diagnosis of poorly differentiated NECs. The high percentage of DLL3 expression in NEC patients also highlights a potential opportunity for a DLL3 targeted therapy in this tumor subset.

Nur mit Berechtigung zugänglich

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker R V., Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61-72.PubMedCrossRef

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335-1342.PubMedPubMedCentralCrossRef

Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G (2017) WHO classification of neoplasms of the neuroendocrine pancreas. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) WHO classification of tumours of endocrine organs. IARC Press, Lyon.

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76(2):182-188.PubMedCrossRef

Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A, Albertelli M, Bianchi A, Circelli L, De Cicco F et al (2018) Open issues on G3 neuroendocrine neoplasms: Back to the future. Endocr Relat Cancer 25(6):R375-R384.PubMedCrossRef

Kawasaki K, Fujii M, Sato T (2018) Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech 11(2).

Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia 19(12):991-1002.PubMedPubMedCentralCrossRef

Kwekkeboom DJ, Krenning EP (2016) Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 30(1):179-91.PubMedCrossRef

Uri I, Grozinsky-Glasberg S (2018) Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 4:16.PubMedPubMedCentralCrossRef

10.

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA (2019) Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 79(1):21-42.PubMedCrossRef

11.

Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G (2019) Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab 10:2042018818804698.PubMedCrossRef

12.

Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G (2012) New treatment strategies in advanced neuroendocrine tumours. Dig Liver Dis 44(2):95-105.PubMedCrossRef

13.

Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T (2015) First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Onco Targets Ther 8:3613-9.PubMedPubMedCentralCrossRef

14.

Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G (2018) Treatment options for PNET liver metastases: A systematic review. World J Surg Oncol 16(1):142.PubMedPubMedCentralCrossRef

15.

Garcia-Carbonero R, Sorbye H, Baudin E et al (2016) ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103(2):186-94.PubMedCrossRef

16.

Kim JY, Hong SM, Ro JY. (2017) Recent updates on grading and classification of neuroendocrine tumors.Ann Diagn Pathol. 11–16.

17.

Tang KH, Basturk O, Sue JJ, Klimstra DS (2016) A Practical Approach to the Classification of WHO Grade 3 (G3) Well differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the Pancreas Am J Surg Pathol.Am J Surg Pathol. 40(9): 1192–1202.

18.

Aster JC, Pear WS, Blacklow SC (2017) The Varied Roles of Notch in Cancer. Annu Rev Pathol 12:245-275.PubMedCrossRef

19.

Kunnimalaiyaan M, Chen H (2007) Tumor Suppressor Role of Notch‐1 Signaling in Neuroendocrine Tumors. Oncologist 12(5):535-42.PubMedCrossRef

20.

Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW (2005) Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90(7):4350-6.PubMedCrossRef

21.

Kunnimalaiyaan M, Yan S, Wong F, Zhang YW, Chen H, Skogseid B, Dackiw APB, Kebebew E (2005) Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 138(6):1137-42.PubMedCrossRef

22.

George J, Walter V, Peifer M et al (2018) Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 9(1):1048.PubMedPubMedCentralCrossRef

23.

Zou B, Zhou XL, Lai SQ, Liu JC (2018) Notch signaling and non-small cell lung cancer. Oncol Lett 15(3):3415-3421.PubMedPubMedCentral

24.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H (2019) Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med 11(484).

25.

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T (2018) Grading of neuroendocrine carcinomas: Correlation of 68 Ga-PET/CT scan with tissue biomarkers. Dis Markers 2018:6878409.PubMedPubMedCentralCrossRef

26.

Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S (2017) Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. J Glob Oncol 3(4):380-388.PubMedCrossRef

27.

Perren A, Couvelard A, Scoazec JY et al (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology 105(3):196-200.PubMedCrossRef

28.

Saunders LR, Bankovich AJ, Anderson WC et al (2015) A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7(302):302ra136.

29.

Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I (2018) Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer 115:116-120.PubMedCrossRef

30.

Thoma C (2019) Targeting DLL3 in neuroendocrine prostate cancer. Nat Rev Urol 16(6):330.PubMedCrossRef

31.

Alcala N, Leblay N, Gabriel AAG et al (2019) Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 10(1):3407.PubMedPubMedCentralCrossRef

32.

Sorbye H, Welin S, Langer SW, et al. (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 24(1):152-60.PubMedCrossRef

33.

Sorbye H, Baudin E, Perren A (2018) The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am 47(3):683-698.PubMedCrossRef

34.

Sigel CS, Krauss Silva VW, Reid MD, et al. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol. 2018;126(1):44-53.PubMedCrossRef

35.

Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199‐1203.PubMedPubMedCentralCrossRef

36.

Chan CS, Laddha SV, Lewis PW et al (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun (1):4158.CrossRef

37.

Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168-177.PubMedCrossRef

38.

Tang LH, Untch BR, Reidy DL, et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016;22(4):1011-1017.PubMedCrossRef

39.

Ito T, Matsuo A, Hassan WA (2016) Notch signaling and Tp53/RB1 pathway in pulmonary neuroendocrine tumorigenesis. Translational Cancer Research 5(2):213-219.CrossRef

40.

Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R (2016) NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer 138(4):927-38.PubMedCrossRef

41.

Rinke A, Gress TM (2017) Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion 95(2):109-114.PubMedCrossRef

42.

Rudin CM, Pietanza MC, Bauer TM et al (2017) Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 18(1):42-51.PubMedCrossRef

43.

Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP (2019) Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: Results from the phase II TrINITY study. Clin Cancer Res 25(23):6958-6966.PubMedPubMedCentralCrossRef

44.

Owen DH, Giffin MJ, Bailis JM, Smit MAD, Carbone DP, He K (2019) DLL3: An emerging target in small cell lung cancer. J Hematol Oncol 12(1):61.PubMedPubMedCentralCrossRef

45.

Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29(1):84-91.PubMedCrossRef

46.

Cunha LL, Marcello MA, Rocha-Santos V, Ward LS (2017) Immunotherapy against endocrine malignancies: Immune checkpoint inhibitors lead the way. Endocr Relat Cancer 24(12):T261-T281.PubMedCrossRef

47.

Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P (2018) Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev 65:78-86.PubMedCrossRef

48.

Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D’Haene N (2018) Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 7(6):661-667.PubMedPubMedCentralCrossRef

49.

Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A (2019) Current perspectives in cancer immunotherapy. Cancers (Basel) 11(10).

50.

Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML (2017) Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis 8(8):e3004.PubMedPubMedCentralCrossRef

51.

Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A (2019) Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. J Pathol Clin Res 5(4):217-226.PubMedPubMedCentralCrossRef

Titel: Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms
verfasst von: Chiara Liverani
Alberto Bongiovanni
Laura Mercatali
Federica Pieri
Chiara Spadazzi
Giacomo Miserocchi
Giandomenico Di Menna
Flavia Foca
Sara Ravaioli
Alessandro De Vita
Claudia Cocchi
Giulio Rossi
Federica Recine
Toni Ibrahim
Publikationsdatum: 06.01.2021
Verlag: Springer US
Erschienen in: Endocrine Pathology / Ausgabe 2/2021
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-020-09657-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms

Abstract

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors

Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms

Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis

Dopamine β-hydroxylase: An Essential and Optimal Immunohistochemical Marker for Pheochromocytoma and Sympathetic Paraganglioma

The Association of Histologically Proven Chronic Lymphocytic Thyroiditis with Clinicopathological Features, Lymph Node Metastasis, and Recurrence Rates of Differentiated Thyroid Cancer

Neu im Fachgebiet Pathologie

Assistierter Suizid durch Infusion von Thiopental

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren